View Author
dai: 067782760
scopus: 16937738600

Vliet, H.H.D.M. van

(Huib van Vliet)


patient plasma esdep liver orthotopic liver transplantation level antiplasmin transplantation 2- antiplasmin levels anhepatic phase phase blood hyperfibrinolysi fibrinolysi 2- antiplasmin anhepatic orthotopic liver transplantation reperfusion study coagulation /detergent plasminogen blood loss factor fibrinogen sd-treated plasma analysis anesthesia cli 60 transfusion requirements /detergent plasma virus transfusion treatment 2 antiplasmin levels group disease 2 antiplasmin table liver disease tranexamic acid anesth intraoperative analg activity difference activator netherland factor viii product tissue-type plasminogen activator fibrinogen degradation products procedure fibrinolytic activity clb amsterdam /detergent virus-inactivated plasma 0.58 iu /ml thromboplastin time 60 min coagulation variables d-dimer esdep-treated p 0.05 sd virus-inactivated plasma aprotinin sd-treated variable antifibrinolytic incidence plasmin inhibitor jonge value infusion hospital preanhepatic induction platelet tranexamic




9 Most Recent Publications

Laboratory diagnosis and molecular basis of mild von willebrand disease type 1 (Article)
Michiels, J.J. Berneman, Z. Gadisseur, A. Planken, M. van der Schroyens, W. Vliet, H.H.D.M. van
2009-06-01
Dominant von willebrand disease type 2A groups i and ii due to missense mutations in the A2 domain of the von willebrand factor gene: Diagnosis and management (Article)
Michiels, J.J. Vliet, H.H.D.M. van
2009-06-01
Managing patients with von willebrand disease type 1, 2 and 3 with desmopressin and von willebrand factor-factor VIII concentrate in surgical settings (Article)
Michiels, J.J. Vliet, H.H.D.M. van Berneman, Z. Schroyens, W. Gadisseur, A.
2009-06-01
ADAMTS-13 and Von Willebrand factor in relation to platelet response during plasma exchange in thrombotic thrombocytopenic purpura: A clue for disease mechanism? (Article)
Kappers-Klunne, M.C. Asten, J.G. van Vliet, H.H.D.M. van
2009-02-12
PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2 (Article)
Vliet, H.H.D.M. van Kappers-Klunne, M.C. Leebeek, F.W.G. Michiels, J.J.
2008-09-01
Evaluation of the AutoDimer D-dimer assay for the exclusion of pulmonary embolism [3] (Article)
Kruip, M.J.H.A. Vliet, H.H.D.M. van Pattynama, P.M.T. Kars, A.H. Meiracker, A.H. van den Jie, K.S-G. Leebeek, F.W.G.
2007-02-01
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients with von Willebrand disease type 1, 2 and 3 (Article)
Michiels, J.J. Vliet, H.H.D.M. van Berneman, Z. Gadisseur, A. Planken, M. van der Schroyens, W. Velden, A. van der Budde, U.
2007-01-01
Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP) (Article)
Jonge, J. de Groenland, T.H.N. Metselaar, H.J. Visser, L.E. Tilanus, H.W. Vliet, H.H.D.M. van IJzermans, J.N.M.
2002-01-01
Acute effect of cigarette smoking on cardiac prostaglandin synthesis and platelet behavior in patients with coronary heart disease (In Book)
Serruys, P.W.J.C. Stoel, I. Hugenholtz, P.G. Leeuw, P.W. de Vliet, H.H.D.M. van Deckmyn, H. Vermylen, J. Giessen, W.J. van der
1983-01-01
  • rss icon RSS Publication Feed
  • foaf icon FOAF Profile